The Protein Brewery’s plan to survive the alt protein slump

The Protein Brewery’s plan to survive the alt protein slump
  • Homepage
  • >
  • All News
  • >
  • The Protein Brewery’s plan to survive the alt protein slump

The Protein Brewery plan to survive alt protein slump (19459000)

Mycoprotein, a fungi-derived protein, is facing a difficult time.

Market data tells a story. Category leader Quorn has seen sales drop, while other players like Sweden’s Mycorena are struggling. Mycorena filed for bankruptcy and was acquired by Naplasol.

The Protein Brewery, a Dutch startup company, plans to thrive in this environment.

Thijs Bos, the newly-appointed CEO of fenix protein says that it’s difficult to find alternative proteins.

What is the key to success in business? He explains that it’s important to distinguish between ingredients that make a real difference and others that don’t. You’ll face a difficult time if you don’t fall into the first category.

What makes The Protein Brewery mycoprotein different?

Bosch believes that The Protein Brewery’s Fermotein mycoprotein will have a significant impact on all aspects of life, including taste, sustainability, nutrition, and affordability.

Fermotein comes from a strain of mycoprotein called Rhizomucorpusillus, which is different than the Fusarium Venenatum used in Quorn or Mycorena. Rhizomucor is a new food, so it needs pre-market approval.

Bosch says that the advantages of this technology outweigh potential regulatory hurdles. The fungus is an extremeophile, which means it grows in low pH and high temperature environments. This makes the capital required to build a factory very limited.

The Protein Brewery will be able to scale up faster. We’re told that once it leaves the factory there are additional benefits. Fermotein, which is mycoprotein in powder form rather than wet mycoprotein biomass makes it a versatile ingredient.

Fermotein and GLP-1: How they align with each other

The Protein Brewery will use nutrition to market its products. Just as taste, affordability, and sustainability are important, (Fermotein has a lower carbon footprint than other plant proteins in terms of land, water, and CO2 emissions), nutrition is also a key component in the marketing strategy.

Bosch agrees, stating that Fermotein is in line with current health trends, such as high-protein diets and GLP-1 medications. The fibre in Fermotein makes it more than just a source of protein.

It’s rich in minerals and contains about 35% fiber, 50% protein.

He says that GLP-1 “exactly aligns” with food ingredients like mycoprotein because it also plays a part in satiety.

Business strategy of the Protein Brewery

The Protein Brewery has closed its EUR30m series B funding round just this month. Novo Holdings – which is the owner of Ozempic manufacturer Novo Nordisk – was amongst investors.

Other companies include Unovis Asset Management (Unovis), Madeli, Invest-NL, and Brabant Development Agency BOM.

The start-up will now focus on the US and Singapore where Fermotein received regulatory approval.

The Dutch company is also very interested in Europe. Bosch says that they are very near to obtaining regulatory approval for Europe.

Bosch is now able to expand its team and invest more in the production of its mycoprotein. This shows that The Protein Brewery’s product, The Protein Brewery’s Mycoprotein, is ready to move out of its lab and onto more products.

Fermotein is being developed for applications that are right for us.

View Article Source

Share Article
Facebook
LinkedIn
X
Berkshire heating engineers put the boiler service first as January bill forecasts climb
As Christmas lists get shorter, Ascot home brand says one lasting piece beats five impulse buys
Ofcom names four age-check methods to underpin the under-16 social media ban
Secret Link